Daisuke Fujisawa

Dr. Daisuke Fujisawa

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Journal of Affective Disorders
Verified
Journal Article
Closed access
DFDaisuke Fujisawa
Daisuke Fujisawa
MMMitsunori Miyashita
Mitsunori Miyashita
SNSatomi Nakajima
Satomi Nakajima
MIMasaya Ito
Masaya Ito
MKMotoichiro Kato
Motoichiro Kato
YKYoshiharu Kim
Yoshiharu Kim

8 July 2015 in Current Breast Cancer Reports
Verified
Journal Article
Closed access
PDF file
DFDaisuke Fujisawa
Daisuke Fujisawa
NHNao Hagiwara
Nao Hagiwara

8 August 2020 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
DFDaisuke Fujisawa
Daisuke Fujisawa
SUShino Umezawa
Shino Umezawa
MFMaiko Fujimori
Maiko Fujimori
MMMitsunori Miyashita
Mitsunori Miyashita
This study aimed to examine the prevalence and associated factors of perceived cancer-related stigma among Japanese cancer survivors. In this web-based survey involving 628 Japanese cancer survivors, perceived cancer-related stigma, quality of life (Quality of Life-Cancer Survivors Instrument), psychological distress (K6) and perceived social support (multidimensional scale of perceived social support) were evaluated. Perceived cancer-related stigma was endorsed by 61.2% of the participants. Perceived cancer-related stigma was significantly associated with quality of life (R = 0.35–0.37), psychological distress (R = 0.35) and perceived social support (R = 0.10). Logistic regression analysis demonstrated that cancer survivors at younger ages (odds ratio = 0.96), with low income (odds ratio = 2.49), with poorer performance status (odds ratio = 2.33), and with breast, urinary or gynecological cancers (odds ratio = 4.27, 4.01, 4.01, respectively) were at higher risk for perceived cancer-related stigma.

27 November 2019 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
PDF file
ANAkira Ninomiya
Akira Ninomiya
MSMitsuhiro Sado
Mitsuhiro Sado
SPSunre Park
Sunre Park
DFDaisuke Fujisawa
Daisuke Fujisawa
TKTeppei Kosugi
Teppei Kosugi
MMMasaru Mimura
Masaru Mimura

1 January 2020 in Heliyon
Verified
Journal Article
Open access
HKHiroaki Kubo
Hiroaki Kubo
HUHiromi Urata
Hiromi Urata
MSMotohiro Sakai
Motohiro Sakai
SNShunsuke Nonaka
Shunsuke Nonaka
KSKazuhiko Saito
Kazuhiko Saito
Takahiro A. KatoTakahiro A. Kato
Takahiro A. Kato
Hikikomori, a severe form of social withdrawal, is increasingly a serious mental health issue worldwide. Hikikomori is comorbid with various psychiatric conditions including depression, social anxiety and suicidal behaviors. Family support is encouraged as a vital first step, however evidence-based programs have yet to be established. Mental Health First Aid (MHFA) is one of the most well-validated educational programs encouraging lay people such as family members, to support close persons suffering from various psychiatric conditions such as depression, anxiety and suicidal behaviors. We newly developed an educational program for family members of hikikomori sufferers mainly based on MHFA and 'Community Reinforcement and Family Training (CRAFT)' with role-play and homework. As a single-arm trial, 21 parents (7 fathers and 14 mothers) living with hikikomori sufferers participated in our program with five once-a-week sessions (2 h per session) and six monthly follow-ups, and its effectiveness was evaluated using various self-rated questionnaires. Perceived skills toward a depressed hikikomori case vignette, stigma held by participants, and subscales of two problematic and one adaptive behaviors of hikikomori sufferers were improved throughout the sessions and follow-ups. In addition, positive behavioral changes of hikikomori sufferers such as improved social participation were reported by participants. Single-arm design and evaluation using self-rated questionnaires are the main limitations of the present study. Our newly developed program has positive effects on family members in their contact and support of hikikomori sufferers. Future trials with control groups are required to validate the effectiveness of this program.

11 February 2019 in Palliative and Supportive Care
Verified
Journal Article
Closed access
PDF file
DFDaisuke Fujisawa
Daisuke Fujisawa
JTJennifer S. Temel
Jennifer S. Temel
JGJoseph A. Greer
Joseph A. Greer
AEAreej El-Jawahri
Areej El-Jawahri
LTLara Traeger
Lara Traeger
WPWilliam F. Pirl
William F. Pirl
Objective: Wearable devices such as a wrist actigraph may have a potential to objectively estimate patients’ functioning and may supplement performance status (PS). This proof-of-concept study aimed to evaluate whether actigraphy data are significantly associated with patients’ functioning and are predictive of their survival in patients with metastatic non-small cell lung cancer.Method: We collected actigraphy data for a three-day period in ambulatory patients with stage IV non-small cell lung cancer. We computed correlations between actigraphy data (specifically, proportion of time spent immobile while awake) and clinician-rated PS, subjective report of physical activities, quality of life (the Functional Assessment of Cancer Therapy – Trial Outcome Index), and survival.Result: Actigraphy data (the proportion of time awake spent immobile) were significantly correlated with Functional Assessment of Cancer Therapy – Trial Outcome Index (r= −0.53,p< 0.001) and with the Eastern Cooperative Oncology Group PS (ECOG PS) (r= 0.37,p< 0.001). The proportion of time awake spent immobile was significantly associated with worse survival. For each 10% increase in this measure, the hazard ratio (HR) was 1.48 (95% confidence interval [CI95%] = 1.06, 2.06) for overall mortality, and odds ratio was 2.99 (CI95%= 1.27, 7.05) for six-month mortality. ECOG PS was also associated with worse survival (HR = 2.80,CI95%= 1.34, 5.86). Among patients with ECOG PS 0-1, the percentage of time awake spent immobile was significantly associated with worse survival, HR = 1.93 (CI95%= 1.10, 3.42), whereas ECOG PS did not predict survival.Significance of Results: Actigraphy may have potential to predict important clinical outcomes, such as quality of life and survival, and may serve to supplement PS. Further validation study is warranted.